127 related articles for article (PubMed ID: 32358723)
1. miR-29b and retinoic acid co-delivery: a promising tool to induce a synergistic antitumoral effect in non-small cell lung cancer cells.
Magalhães M; Jorge J; Gonçalves AC; Sarmento-Ribeiro AB; Carvalho R; Figueiras A; Santos AC; Veiga F
Drug Deliv Transl Res; 2020 Oct; 10(5):1367-1380. PubMed ID: 32358723
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA-29b attenuates non-small cell lung cancer metastasis by targeting matrix metalloproteinase 2 and PTEN.
Wang H; Guan X; Tu Y; Zheng S; Long J; Li S; Qi C; Xie X; Zhang H; Zhang Y
J Exp Clin Cancer Res; 2015 Jun; 34(1):59. PubMed ID: 26063204
[TBL] [Abstract][Full Text] [Related]
3. miR-29b inhibits non-small cell lung cancer progression by targeting STRN4.
Xie Y; Zhao F; Zhang P; Duan P; Shen Y
Hum Cell; 2020 Jan; 33(1):220-231. PubMed ID: 31813135
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of RAC1-GEF DOCK3 by miR-512-3p contributes to suppression of metastasis in non-small cell lung cancer.
Zhu X; Gao G; Chu K; Yang X; Ren S; Li Y; Wu H; Huang Y; Zhou C
Int J Biochem Cell Biol; 2015 Apr; 61():103-14. PubMed ID: 25687035
[TBL] [Abstract][Full Text] [Related]
5. Expression analysis of three miRNAs, miR-26a, miR-29b and miR-519d, in relation to MMP-2 expression level in non-small cell lung cancer patients: a pilot study.
Pastuszak-Lewandoska D; Kordiak J; Czarnecka KH; Migdalska-Sęk M; Nawrot E; Domańska-Senderowska D; Kiszałkiewicz JM; Antczak A; Górski P; Brzeziańska-Lasota E
Med Oncol; 2016 Aug; 33(8):96. PubMed ID: 27447710
[TBL] [Abstract][Full Text] [Related]
6. c-Myc suppresses microRNA-29b to promote tumor aggressiveness and poor outcomes in non-small cell lung cancer by targeting FHIT.
Wu DW; Hsu NY; Wang YC; Lee MC; Cheng YW; Chen CY; Lee H
Oncogene; 2015 Apr; 34(16):2072-82. PubMed ID: 24909176
[TBL] [Abstract][Full Text] [Related]
7. miR-34a and miR-15a/16 are co-regulated in non-small cell lung cancer and control cell cycle progression in a synergistic and Rb-dependent manner.
Bandi N; Vassella E
Mol Cancer; 2011 May; 10():55. PubMed ID: 21575235
[TBL] [Abstract][Full Text] [Related]
8. The mechanism involved in the loss of PTEN expression in NSCLC tumor cells.
Li G; Zhao J; Peng X; Liang J; Deng X; Chen Y
Biochem Biophys Res Commun; 2012 Feb; 418(3):547-52. PubMed ID: 22290228
[TBL] [Abstract][Full Text] [Related]
9. TNFAIP2 Promotes Non-Small Cell Lung Cancer Cells and Targeted by miR-145-5p.
Li J; Song Y; Yu B; Yu Y
DNA Cell Biol; 2020 Jul; 39(7):1256-1263. PubMed ID: 32456459
[TBL] [Abstract][Full Text] [Related]
10. ROR1-targeted delivery of miR-29b induces cell cycle arrest and therapeutic benefit in vivo in a CLL mouse model.
Chiang CL; Goswami S; Frissora FW; Xie Z; Yan PS; Bundschuh R; Walker LA; Huang X; Mani R; Mo XM; Baskar S; Rader C; Phelps MA; Marcucci G; Byrd JC; Lee LJ; Muthusamy N
Blood; 2019 Aug; 134(5):432-444. PubMed ID: 31151986
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic delivery of microRNA-143 by cationic lipoplexes for non-small cell lung cancer treatment in vivo.
Jiang Q; Yuan Y; Gong Y; Luo X; Su X; Hu X; Zhu W
J Cancer Res Clin Oncol; 2019 Dec; 145(12):2951-2967. PubMed ID: 31654121
[TBL] [Abstract][Full Text] [Related]
12. Metformin-repressed miR-381-YAP-snail axis activity disrupts NSCLC growth and metastasis.
Jin D; Guo J; Wu Y; Chen W; Du J; Yang L; Wang X; Gong K; Dai J; Miao S; Li X; Su G
J Exp Clin Cancer Res; 2020 Jan; 39(1):6. PubMed ID: 31906986
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA expression and clinical outcome of small cell lung cancer.
Lee JH; Voortman J; Dingemans AM; Voeller DM; Pham T; Wang Y; Giaccone G
PLoS One; 2011; 6(6):e21300. PubMed ID: 21731696
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic priming of non-small cell lung cancer cell lines to the antiproliferative and differentiating effects of all-trans retinoic acid.
Greve G; Schiffmann I; Lübbert M
J Cancer Res Clin Oncol; 2015 Dec; 141(12):2171-80. PubMed ID: 26008188
[TBL] [Abstract][Full Text] [Related]
15. Identification of key microRNAs and hub genes in non-small-cell lung cancer using integrative bioinformatics and functional analyses.
Song F; Xuan Z; Yang X; Ye X; Pan Z; Fang Q
J Cell Biochem; 2020 Mar; 121(3):2690-2703. PubMed ID: 31692035
[TBL] [Abstract][Full Text] [Related]
16. microRNA-381 suppresses the growth and increases cisplatin sensitivity in non-small cell lung cancer cells through inhibition of nuclear factor-κB signaling.
Huang RS; Zheng YL; Zhao J; Chun X
Biomed Pharmacother; 2018 Feb; 98():538-544. PubMed ID: 29287202
[TBL] [Abstract][Full Text] [Related]
17. Ultrasound-targeted microbubble destruction mediated miR-492 inhibitor suppresses the tumorigenesis in non-small cell lung cancer.
Zou W; Wang Y; Song Q; Li Q; Ren J; Liu X; Cui W
Ann Med; 2021 Dec; 53(1):2246-2255. PubMed ID: 34818961
[TBL] [Abstract][Full Text] [Related]
18. Encapsulated miR-200c and Nkx2.1 in a nuclear/mitochondria transcriptional regulatory network of non-metastatic and metastatic lung cancer cells.
D'Almeida O; Mothar O; Bondzie EA; Lieumo Y; Tagne L; Gupta S; Volkert T; Levine S; Tagne JB
BMC Cancer; 2019 Feb; 19(1):136. PubMed ID: 30744585
[TBL] [Abstract][Full Text] [Related]
19. circ_0007385 served as competing endogenous RNA for miR-519d-3p to suppress malignant behaviors and cisplatin resistance of non-small cell lung cancer cells.
Ye Y; Zhao L; Li Q; Xi C; Li Y; Li Z
Thorac Cancer; 2020 Aug; 11(8):2196-2208. PubMed ID: 32602212
[TBL] [Abstract][Full Text] [Related]
20. GAS5 knockdown reduces the chemo-sensitivity of non-small cell lung cancer (NSCLC) cell to cisplatin (DDP) through regulating miR-21/PTEN axis.
Cao L; Chen J; Ou B; Liu C; Zou Y; Chen Q
Biomed Pharmacother; 2017 Sep; 93():570-579. PubMed ID: 28686971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
